0.86
-0.03(-3.37%)
Currency In USD
| Previous Close | 0.89 |
| Open | 0.9 |
| Day High | 0.94 |
| Day Low | 0.85 |
| 52-Week High | 5.1 |
| 52-Week Low | 0.8 |
| Volume | 229,083 |
| Average Volume | 1.67M |
| Market Cap | 22.61M |
| PE | -0.3 |
| EPS | -2.87 |
| Moving Average 50 Days | 1.18 |
| Moving Average 200 Days | 1.88 |
| Change | -0.03 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $8.62 as of February 21, 2026 at a share price of $0.86. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $56.21 as of February 21, 2026 at a share price of $0.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
GlobeNewswire Inc.
Yesterday at 1:50 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platfo
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
GlobeNewswire Inc.
Feb 11, 2026 1:35 PM GMT
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indicatio
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
GlobeNewswire Inc.
Feb 03, 2026 2:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platfo